Nkarta, Inc. (NKTX) Stock Forecast & Price Target

Nkarta is viewed as fundamentally attractive because its allogeneic, off-the-shelf NK-cell platform may overcome key autologous CAR-T constraints, including manufacturing complexity, limited scalability, and higher cost, while preserving potent cytotoxic activity. Its lead candidate NKX019 could serve as a differentiated proof point, with modeled peak U.S. sales of about $2 billion in SLE and a plausible path to market supported by ongoing Ntrust-1 and Ntrust-2 trials and potential outpatient dosing that may speed enrollment. The bullish case is further reinforced by encouraging competitor data in lupus and SSc, favorable early safety with no CRS or ICANs, and the view that the stock is undervalued relative to peer valuations and platform optionality.

Nkarta is viewed negatively because its clinical-stage model remains highly speculative, with all programs still in early development and no FDA- or EMA-approved NK cell therapies to validate the platform. 2Q26 operating expenses rose to $43.1M, up 40% from 1Q26 and above expectations, while EPS was ($0.54), highlighting meaningful cash burn as it continues enrolling Ntrust-1 and Ntrust-2 trials. Although it ended 2Q26 with $243.2M in cash and equivalents, the need for additional financing, combined with regulatory, clinical, and competitive uncertainty, leaves the outlook pressured.